-
CANbridge Announces Marketing Approval of CAN108 (迈芮倍®/LIVMARLI®) in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
-LIVMARLI First and Only Treatment Approved in Mainland China for Cholestatic Pruritus in ALGS
-CANbridge to Hold Investor Call
20230601 -
CANbridge to Participate in the Jefferies 2023 Global Healthcare Conference
20230531 -
CANbridge Announces Full Enrollment Reached in China Region of the Global LIVMARLI® (CAN108) EMBARK Phase 2 Study in Biliary Atresia
20230530 -
CANbridge and UMass Chan Medical School Spinal Muscular Atrophy Gene Therapy (CAN203) Improves Lifespan and Motor Function in Mice When Administered via Intracerebroventricular Injection
-Data Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
20230517 -
CANbridge Pharmaceuticals Appoints Jason West Vice President, Head of Gene Therapy Research
20230506 -
CANbridge-UMass Chan Medical School Spinal Muscular Atrophy Gene Therapy Animal Data to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
-Novel Second-Generation SMA Gene Therapy Rescues Motor Function in Mice, Outperforms Benchmark Therapy
20230505 -
CANbridge Pharmaceuticals Spinal Muscular Atrophy Gene Therapy Abstract Accepted for Presentation at the American Society for Gene and Cell Therapy Annual Meeting
20230413 -
CANbridge Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2022
20230331 -
CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China Reaches Full Enrollment
-Recent CAN008 Phase 1 Follow-Up Data Showed 67% 5-Year Overall Survival in High-Dose Cohort, Reported at ESMO Sarcoma and Rare Cancers
20230329
Media Reports
Press Release